Determinants of Enrollment in a Preventive HIV Vaccine Trial
- 1 May 2004
- journal article
- research article
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 36 (1) , 604-612
- https://doi.org/10.1097/00126334-200405010-00009
Abstract
Objective: To compare hypothetical and actual willingness to enroll in a preventive HIV vaccine trial and identify factors affecting enrollment. Methods: Participants previously enrolled in an HIV vaccine preparedness study (VPS) in 8 US cities were invited to be screened for a phase 2 HIV vaccine trial. Demographic and risk characteristics of those enrolling, ineligible, and refusing enrollment were compared using the χ2 or Fisher exact test. Multivariable logistic models were used to identify independent predictors of refusal. Results: Of 2531 high-risk HIV-uninfected former VPS participants contacted for the vaccine trial, 13% enrolled, 34% were ineligible, and 53% refused enrollment. Only 20% of those stating hypothetical willingness during the VPS actually enrolled in this vaccine trial. In multivariate analysis, refusal was higher among African Americans and lower in persons >40 years of age, those attending college, and those with ≥5 partners in the prior 6 months. All racial ethnic groups cited concerns about vaccine-induced seropositivity; African Americans also cited mistrust of government and safety concerns as barriers to enrollment. Conclusions: Steps can be taken to minimize potential social harms and to mobilize diverse communities to enroll in trials. Statements of hypothetical willingness to participate in future trials may overestimate true enrollment.Keywords
This publication has 37 references indexed in Scilit:
- Willingness to Participate and Enroll in a Phase 3 Preventive HIV-1 Vaccine TrialJAIDS Journal of Acquired Immune Deficiency Syndromes, 2002
- Who Will Enroll? Predicting Participation in a Phase II AIDS Vaccine TrialJAIDS Journal of Acquired Immune Deficiency Syndromes, 2001
- Safety and Immunogenicity of a Canarypox‐Vectored Human Immunodeficiency Virus Type 1 Vaccine with or without gp120: A Phase 2 Study in Higher‐ and Lower‐Risk VolunteersThe Journal of Infectious Diseases, 2001
- Are US Populations Appropriate for Trials of Human Immunodeficiency Virus Vaccine?American Journal of Epidemiology, 2001
- Factors Related to the Willingness of Young Gay Men to Participate in Preventive HIV Vaccine TrialsJAIDS Journal of Acquired Immune Deficiency Syndromes, 1999
- Population effects of preventive and therapeutic HIV vaccines in early- and late-stage epidemicsAIDS, 1998
- Readiness of high-risk populations in the HIV Network for Prevention Trials to participate in HIV vaccine efficacy trials in the United StatesAIDS, 1998
- Feasibility of Human Immunodeficiency Virus Vaccine Trials in Homosexual Men in the United States: Risk Behavior, Seroincidence, and Willingness to ParticipateThe Journal of Infectious Diseases, 1996
- The feasibility of HIV-1 vaccine efficacy trials among gay/bisexual men in New York City: Project ACHIEVEAIDS, 1996
- Interest among Gay/Bisexual Men in Greater Boston in Participating in Clinical Trials of Preventive HIV VaccinesJAIDS Journal of Acquired Immune Deficiency Syndromes, 1996